NEW RESEARCH·Farah et al., JACC 2026

40–50% of your
heart attack risk
is in your genome.

Your genome is the most important predictor of your future heart attack risk.

A landmark study of 215,695 people proves it. Your cholesterol panel alone can't see it. But a single genome test plus three biomarkers — read once — can predict your lifetime heart attack risk more accurately than any traditional methodology.

Start Genome Testing at $599 →See the science

50%

Genetic Risk

Source: Farah W. et al.,
Journal of the American College of Cardiology, 2026

The Scale of the Problem

Every year, 3 million Americans have a heart attack. Most of them didn't see it coming.

They had checkups. They knew their cholesterol. Some even had “good” numbers. What they didn't know — what no standard test measured — was the genetic blueprint already shaping their risk since birth.

Americans have a heart attack each year

Heart disease is the #1 cause of death in America. Every year. By a wide margin.

of your lifetime risk is written in your DNA

Proven in a study of 215,695 people. Your genome carries more information about your cardiac future than your last 10 blood tests combined.

of high-risk people are never identified by standard care

Familial hypercholesterolemia affects 1 in 250 Americans. Nine out of ten have never been told. Their DNA knew. Their doctor didn't.

"She had a normal physical every year. Normal cholesterol. Normal blood pressure. The heart attack came at 47."

Her genome would have flagged it at 35.

Why Your Annual Physical Isn't Enough

Standard tests measure what disease has already done. Your genome measures what it will do.

Blood pressure, cholesterol, and an EKG measure the consequences of years of biological processes already underway. They're essential — but they're looking at the past. Your genome is the blueprint. It tells you what's coming.

CAD Genetic Risk Score

Predicts your lifetime susceptibility — strongest in ages 40–49, before symptoms appear

Inherited LDL (FH)

Single gene variants that triple lifetime cholesterol exposure — invisible to standard lipid panels

Inflammatory Pathway

Genetic variants driving chronic inflammation that standard CRP tests don't predict

Lp(a) Risk

Causes 1 in 5 heart attacks. Almost entirely genetic. Rarely tested. Highly actionable.

From the research: In a study of 215,695 UK Biobank participants followed for 12 years, genetic factors (CAD PRS) contributed 48.2% of all early-onset coronary risk — independent of cholesterol and blood pressure. Farah et al., JACC 2026.

The Human Longevity Difference

Our algorithm catches 61% more heart attacks before they happen.

Built on the same research published in the Journal of the American College of Cardiology, Human Longevity's 4-biomarker algorithm — combining your genetic risk score with lipid and inflammation markers — dramatically outperforms standard care at identifying who needs intervention now.

Standard Care (PCE Alone)

1,445

CAD events prevented
per 100,000 screened adults

+61%

MORE LIVES

→

Human Longevity 4-Biomarker Model

2,339

CAD events prevented
per 100,000 screened adults

The 4 Biomarkers That Change Everything

CAD PRS

1.79× hazard ratio

Your inherited genetic risk score — the strongest single predictor of lifetime CAD

LDL-C

1.60× hazard ratio

Elevated "bad" cholesterol, especially dangerous when genetically driven

hsCRP

1.64× hazard ratio

Inflammatory marker that predicts plaque instability and rupture risk

Lp(a)

1.20× hazard ratio

Inherited cholesterol particle responsible for 1 in 5 heart attacks

Based on: Farah W. et al., "The Biological Blueprint of Coronary Risk: Integrating Genomics, Lipids, and Inflammation to Predict CAD Before Clinical Symptoms Appear." Journal of the American College of Cardiology (JACC), 2026. UK Biobank, N=215,695, 12-year follow-up. Hazard ratios represent independent associations adjusted for age, sex, and traditional risk factors.

The Window of Opportunity

The research shows the best time to test is your 40s. Most people wait until it's too late.

In the JACC study, the 4-biomarker algorithm was most powerful precisely in patients aged 40–49 — because biological risk is already accumulating decades before any symptom appears. By your 60s, lifestyle damage has already compounded. The genome was always there, but the window to act early is closing.

Ages 40–49

13.8×

Risk increase with all 4 markers elevated

Ages 50–59

4.2×

Risk increase with all 4 markers elevated

Ages 60–69

2.6×

Risk increase with all 4 markers elevated

Bottom line: The earlier you test, the longer you have to act. A 40-year-old who discovers elevated CAD PRS + high LDL-C faces a 13.8× higher risk — and has 20 years to aggressively reduce it before symptoms ever appear.

What You'll Know After Your Test

Six things about your heart no blood panel has ever shown you.

One saliva sample. Sequenced once in a CLIA-certified lab at 30× clinical coverage. Returns a physician-ready report your cardiologist can act on.

Your Coronary Artery Disease Polygenic Risk Score

Most Important

Your individual lifetime genetic risk for heart attack — calibrated against data from hundreds of thousands of sequenced genomes. The single most powerful predictor of cardiac risk available today. Standard care never measures it.

Familial Hypercholesterolemia (FH) Screening

Variants in PCSK9, LDLR, and APOB — the three genes that cause inherited high cholesterol regardless of diet or exercise. 1 in 250 people carry one. 90% have never been told. A single PCSK9 variant raises heart attack risk by 79%.

Lp(a) Genetic Prediction

Lipoprotein(a) drives 1 in 5 heart attacks and is almost entirely written in your DNA. It does not respond to statins. Most cardiologists have never tested for it. Knowing unlocks emerging RNA-interference therapies.

Hereditary Arrhythmia & Cardiomyopathy Panel

Long QT syndrome, hypertrophic cardiomyopathy, Brugada syndrome — inherited conditions that cause sudden cardiac death in people with no prior symptoms. Often the first sign is the last.

Cardiovascular Pharmacogenomics

Your genes determine how you metabolize statins, anticoagulants, and beta-blockers. Knowing this helps your physician prescribe the right drug, at the right dose, on the first try — avoiding adverse reactions and ineffective treatments.

Lifetime Re-Analysis — Free, Every Year

Your genome doesn't change. The science does. Every year, we re-run your data through the latest published algorithms and update your report with any new clinically actionable findings. At no additional cost. Ever.

How It Works

From your kitchen to your cardiologist. In 4 steps.

Order Online

Kit ships in 2 business days. $599, one-time. HSA/FSA accepted. No clinic visit required.

Spit in a Tube

A simple saliva collection. Takes 5 minutes at home. Mail it back in the prepaid envelope.

Clinical-Grade Sequencing

Processed in a CLIA-certified lab. 30× whole genome coverage. AI-analyzed against the largest private genomic database in the world.

Your Report

Clinician-formatted PDF in 4–6 weeks. Physician-ready. Share directly with your cardiologist or primary care physician.

"We are no longer just treating disease. We are predicting and preventing it — before it ever begins. The genome is where that story starts.

Dr. Wei-Wu He, PhD

Executive Chairman, Human Longevity, Inc.
Cloned the original PSA gene · Founding scientist, Human Genome Sciences

Your Questions

What people ask before ordering.

Consumer kits scan less than 0.1% of your DNA using a genotyping chip — they look at a few hundred thousand fixed spots. Whole genome sequencing reads all 6.4 billion base pairs. Many cardiovascular variants, including familial hypercholesterolemia mutations and the full CAD polygenic risk score, sit outside what consumer kits ever look at. It's the difference between reading a chapter and reading the entire book.

Yes — and this is exactly the point. The JACC study found that 48% of early-onset coronary risk is driven by genetics, independent of cholesterol. People with completely normal lipid panels still carry CAD polygenic risk scores that triple their lifetime heart attack probability. Lp(a) — responsible for 1 in 5 heart attacks — is almost invisible to a standard lipid panel but fully visible in your genome.

Your report is designed to hand to your physician. We provide a clinician-formatted PDF with actionable findings, thresholds, and relevant literature references. For Executive Health members, our clinical team handles follow-up directly. For Genomics-only clients, we provide the data — treatment decisions remain with your licensed physician.

No. You sequence your genome once. It doesn't change. The $599 covers sequencing, your initial report, and lifetime re-analysis as the science advances. We re-run your data against new published algorithms every year and update your report with any newly discovered actionable findings — at no additional cost.

In a hypothetical cohort of 100,000 borderline-risk adults, adding the 4-biomarker genomic model to standard care (PCE) increased targeted statin eligibility by 32.3% (Net Reclassification Index). Translating that into events: standard care prevented 1,445 CAD events; the biological model prevented 2,339 — a 61% improvement. This is from Farah et al., JACC 2026, based on real outcomes across 215,695 UK Biobank participants followed for 12 years.

Human Longevity was founded in 2013 by Dr. J. Craig Venter — the scientist who led the first sequencing of the human genome. The company has invested over $600 million building genomic databases and algorithms over a decade. Our scientific advisory board includes Nobel Laureates Geoffrey Hinton (AI) and Michael Levitt (computational biology). The algorithms underlying this report are built on and validated against the same body of research as the JACC 2026 paper.

One Test. A Lifetime of Knowing.

Stop guessing about your heart.

3 million Americans will have a heart attack this year. Half of them are carrying genetic risk their doctors have never seen. For $599 — one-time, HSA/FSA eligible, same clinical-grade lab as our $8,000 Executive Health program — you can see yours.

Order Your Genome — $599 →Learn about Executive Health →

Questions? Call a clinical specialist: 844-838-3322

Primary Citation: Farah, R. et al. Combining genomics with lipid and inflammatory biomarkers to predict coronary artery disease risk: UK Biobank study. J. Am. Coll. Cardiol. 87, 2785–2803 (2026). UK Biobank, N=215,695, 12-year follow-up. · This page is for educational purposes. Individual results vary. Heart attack risk prediction and prevention requires evaluation by a licensed clinician. Human Longevity, Inc. is not the author of the referenced study.